Autoimmune Disease Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||390619|
|出版日||ページ情報||英文 114 Pages
|世界の自己免疫疾患診断市場：成長、動向、予測 Autoimmune Disease Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年05月01日||ページ情報: 英文 114 Pages||
The autoimmune disease diagnostics market is expected to register a CAGR of nearly 7.9% during the forecast period, 2019-2024.
Autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. Diagnosis of potential autoimmune diseases is very difficult because not one laboratory test alone can produce diagnosis results for the disease. Hence, multiple laboratory tests are needed, and this includes basic studies, like complete blood count, comprehensive metabolic panel, acute phase reactants, immunologic studies, serologies, flow cytometry, cytokine analysis, and HLA typing. Although some tests may be non-specific, such as the erythrocyte sedimentation rate (ESR), they are useful to assess the disease activity. These tests can be useful in the diagnosis and management of patients suffering from autoimmune diseases and help in providing a prognosis or indicating the severity of organ involvement or damage.
Immunologic Assays Segment Dominates the Autoimmune Disease Diagnostics Market
Autoimmune disease diagnostics market is segmented on the basis of disease type and diagnosis. Diagnosis is again segmented into regular laboratory tests, inflammatory markers, immunologic assays, antibody tests, and other tests.
The immunologic assays segment is expected to register a healthy CAGR over the forecast period. Factors that are responsible for the growth of this market include cost-effectiveness, growth in the biotechnology and pharmaceutical sectors, and high sensitivity and specificity of immunoassays. When compared to conventional tests, immunologic assays have been proven to provide highly accurate results, even with very small samples. Immunologic reactions are highly specific, as they can take place only in the presence of proper immunologic agents. For instance, an antibody against a viral protein cannot bind with an antigen that is derived from bacteria. This high specificity indicates high accuracy in results, enabling high sensitivity in the detection of diseases. This high sensitivity not only helps in easy detection, but also eliminates the need for secondary verifications, which ultimately saves costs. For instance, in December 2018, Quidel received a CE mark approval for its product Quidel's Sofia 2 Lyme+ FIA for use with the Sofia 2 Fluorescent Immunoassay Analyzer.
Asia-Pacific is the Fastest Growing Region in the Autoimmune Disease Diagnostics Market
Asia-Pacific is anticipated to exhibit extensive market growth over the forecast period, owing to the presence of rising disposable income and increasing patient pool in the emerging countries. Furthermore, growing awareness regarding the benefits of early and accurate diagnosis of autoimmune diseases to seek right treatment, rising development of healthcare infrastructure, and growing healthcare expenditure are likely to boost the growth of the autoimmune disease diagnostics market in the Asia-Pacific region.
The Japanese autoimmune disease diagnostics market holds the largest market share in the Asia-Pacific region, and registered a healthy CAGR, due to the presence of a large population with the autoimmune condition in the country, as of 2017. Growth strategies adopted by the local and international players in the Asia-Pacific region is also propelling the growth of the autoimmune disease diagnostics market. In 2017, ImmunArray, a privately-held molecular device diagnostic company, and Kindstar Global Co. Ltd, a specialty clinical testing company based in Wuhan, forged a partnership to undertake joint clinical testing for lupus, due to the growing prevalence of the disease in China.
The market comprises of major market players, and these players are focusing on R&D activities and significant growth strategies. Recently, a few diagnostic companies entered into strategic partnerships with hospitals. This trend is expected to continue over the next few years, in order to meet the high volume of patient needs, across different regions. In July 2017, AARDA, in partnership with the Relapsing Polychondritis Awareness & Support Foundation (RPASF), hosted the first Bowling Green Autoimmune Walk and Warriors 5K Fun Run to raise awareness and funding for innovative research. In May 2017, Thermo Fisher Scientific acquired Patheon. In June 2017, Abbott introduced the Alinity HG hematology analyzer, the newest addition to the Alinity family of harmonized systems. In June 2017, Bio-Rad signed an agreement with VISIA imaging for fully-automated IFA Slide Processing and Reading System. Thus, the market has been witnessing technological developments on a large scale for the past couple of years.